La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Jafron BiomedicalLtd Gestione

Gestione criteri di controllo 2/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Fan Dong

Amministratore delegato

CN¥3.7m

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	13.9yrs
Proprietà del CEO	45.9%
Durata media del management	1.6yrs
Durata media del Consiglio di amministrazione	3.2yrs

Aggiornamenti recenti sulla gestione

Recent updates

Jafron BiomedicalLtd's (SZSE:300529) Dividend Will Be Reduced To CN¥0.40

May 28

A Look At The Intrinsic Value Of Jafron Biomedical Co.,Ltd. (SZSE:300529)

May 24

Why Investors Shouldn't Be Surprised By Jafron Biomedical Co.,Ltd.'s (SZSE:300529) 30% Share Price Surge

May 08

Jafron BiomedicalLtd's (SZSE:300529) Soft Earnings Don't Show The Whole Picture

May 02

Investors Could Be Concerned With Jafron BiomedicalLtd's (SZSE:300529) Returns On Capital

Apr 13

Does Jafron BiomedicalLtd (SZSE:300529) Have A Healthy Balance Sheet?

Mar 22

Jafron Biomedical Co.,Ltd.'s (SZSE:300529) P/E Is Still On The Mark Following 31% Share Price Bounce

Mar 04

AMMINISTRATORE DELEGATO

Fan Dong (54 yo)

13.9yrs

Mandato

CN¥3,741,000

Compensazione

Mr. Fan Dong serves as Chairman of Board of Directors and General Manager at Jafron Biomedical Co., Ltd. He serves as Director since April 27, 2023 at Jafron Biomedical Co.,Ltd. He served as Company Secret...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Fan Dong	Chairman of Board of Directors & GM	no data	CN¥3.74m	45.86% CN¥ 9.0b
Xueyun Liao	Director & Financial Director	1.3yrs	CN¥500.50k	0.019% CN¥ 3.7m
De Zhi Li	Deputy General Manager	no data	CN¥865.40k	0.46% CN¥ 89.7m
Xian Min Tang	Deputy GM & Director	no data	CN¥2.65m	2.76% CN¥ 541.3m
Aijun Wu	Deputy General Manager	4.3yrs	CN¥2.44m	0.031% CN¥ 6.2m
Rui Wang	General Manager	less than a year	CN¥510.40k	Nessun dato
Cong Huang	Board Secretary	1.9yrs	CN¥455.20k	0.00044% CN¥ 86.3k

1.6yrs

Durata media

54yo

Età media

Gestione esperta: Il team dirigenziale di 300529 non è considerato esperto (durata media 1.6 anni), il che suggerisce un nuovo team.

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Fan Dong	Chairman of Board of Directors & GM	13.9yrs	CN¥3.74m	45.86% CN¥ 9.0b
Xueyun Liao	Director & Financial Director	less than a year	CN¥500.50k	0.019% CN¥ 3.7m
Xian Min Tang	Deputy GM & Director	13.9yrs	CN¥2.65m	2.76% CN¥ 541.3m
Claudio Ronco	Member of Global Advisory Board	3.2yrs	Nessun dato	Nessun dato
Feng Li	Non-Independent Director	4.3yrs	CN¥1.08m	0.099% CN¥ 19.4m
Xiaohong Peng	Chairman of Supervisory Board	4.3yrs	Nessun dato	Nessun dato
Wen Lei	Non-Independent Director	4.3yrs	CN¥177.20k	Nessun dato
Rinaldo Bellomo	Member of Global Advisory Board	3.2yrs	Nessun dato	Nessun dato
Thomas Rimmelé	Member of Global Advisory Board	3.2yrs	Nessun dato	Nessun dato
John Prowle	Member of Global Advisory Board	3.2yrs	Nessun dato	Nessun dato
Antoine Schneider	Member of Global Advisory Board	3.2yrs	Nessun dato	Nessun dato
Olivier Joannes-Boyau	Member of Global Advisory Board	3.2yrs	Nessun dato	Nessun dato

3.2yrs

Durata media

54yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di 300529 sono considerati esperti (durata media dell'incarico 3.2 anni).

Jafron BiomedicalLtd Gestione

Gestione criteri di controllo 2/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Jafron Biomedical Co.,Ltd., Annual General Meeting, May 20, 2024

High number of new directors

High number of new and inexperienced directors

High number of new and inexperienced directors

Recent updates

Second quarter 2024 earnings released: EPS: CN¥0.34 (vs CN¥0.10 in 2Q 2023)

Jafron Biomedical Co.,Ltd. to Report First Half, 2024 Results on Aug 08, 2024

Jafron BiomedicalLtd's (SZSE:300529) Dividend Will Be Reduced To CN¥0.40

Dividend reduced to CN¥0.40

A Look At The Intrinsic Value Of Jafron Biomedical Co.,Ltd. (SZSE:300529)

Why Investors Shouldn't Be Surprised By Jafron Biomedical Co.,Ltd.'s (SZSE:300529) 30% Share Price Surge

Now 20% overvalued after recent price rise

Jafron BiomedicalLtd's (SZSE:300529) Soft Earnings Don't Show The Whole Picture

Jafron Biomedical Co.,Ltd., Annual General Meeting, May 20, 2024

Jafron Biomedical Co.,Ltd. Proposes Final Dividend for the Year 2023

First quarter 2024 earnings released: EPS: CN¥0.35 (vs CN¥0.25 in 1Q 2023)

Investors Could Be Concerned With Jafron BiomedicalLtd's (SZSE:300529) Returns On Capital

Jafron Biomedical Co.,Ltd. to Report Q1, 2024 Results on Apr 26, 2024

Does Jafron BiomedicalLtd (SZSE:300529) Have A Healthy Balance Sheet?

Investor sentiment improves as stock rises 15%

Jafron Biomedical Co.,Ltd.'s (SZSE:300529) P/E Is Still On The Mark Following 31% Share Price Bounce

Investor sentiment improves as stock rises 16%

Jafron Biomedical Co.,Ltd. to Report Fiscal Year 2023 Results on Apr 26, 2024

New minor risk - Earnings quality

Third quarter 2023 earnings released: EPS: CN¥0.18 (vs CN¥0.16 in 3Q 2022)

Consensus revenue estimates fall by 13%

Investor sentiment improves as stock rises 16%

Jafron Biomedical Co.,Ltd. to Report Q3, 2023 Results on Oct 30, 2023

New minor risk - Profit margin trend

Second quarter 2023 earnings released: EPS: CN¥0.10 (vs CN¥0.51 in 2Q 2022)

Jafron Biomedical Co.,Ltd. to Report First Half, 2023 Results on Aug 23, 2023

Jafron Biomedical Co.,Ltd. Announces Cash Dividend on A Shares for the Year 2022, Payable on 31 May 2023

High number of new directors

Full year 2022 earnings: EPS and revenues miss analyst expectations

High number of new and inexperienced directors

Investor sentiment deteriorated over the past week

Third quarter 2022 earnings released: EPS: CN¥0.16 (vs CN¥0.30 in 3Q 2021)

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS: CN¥0.51 (vs CN¥0.43 in 2Q 2021)

Jafron Biomedical Co.,Ltd. Implements Final Cash Dividend (A Shares) for 2021, Payable on 10 June 2022

Jafron Biomedical Co.,Ltd. Approves Profit Distribution

Price target decreased to CN¥56.67

High number of new and inexperienced directors

Jafron Biomedical Co.,Ltd. Announces the Profit Distribution Proposal for 2021

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Investor sentiment deteriorated over the past week

Price target decreased to CN¥73.99

Third quarter 2021 earnings released: EPS CN¥0.30 (vs CN¥0.23 in 3Q 2020)

Jafron Biomedical Co.,Ltd. (SZSE:300529) commences an Equity Buyback Plan for CNY 500 million worth of its shares, under the authorization approved on September 14, 2021.

Second quarter 2021 earnings released: EPS CN¥0.43 (vs CN¥0.32 in 2Q 2020)

Investor sentiment deteriorated over the past week

Jafron Biomedical Co.,Ltd. Announces 2020 Final Profit Distribution, Payable on 12 May 2021

Full year 2020 earnings released: EPS CN¥1.10 (vs CN¥0.73 in FY 2019)

Jafron Biomedical Co.,Ltd. to Report Fiscal Year 2020 Results on Apr 01, 2021

New 90-day high: CN¥84.63

New 90-day low: CN¥64.16

Market pulls back on stock over the past week

Price target raised to CN¥95.66

New 90-day high: CN¥78.75

Price target raised to CN¥52.96

Third quarter earnings released

Jafron Biomedical Co.,Ltd. to Report Q3, 2020 Results on Oct 21, 2020

New 90-day low: CN¥64.37

New 90-day high - CN¥77.44

Earnings released

Jafron Biomedical Co.,Ltd. to Report First Half, 2020 Results on Aug 26, 2020

AMMINISTRATORE DELEGATO

Mandato

Compensazione

Gruppo dirigente

Durata media

Età media

Membri del Consiglio di amministrazione

Durata media

Età media